Julius Clinical
Pieter van der Meer has a significant background in finance and control, with experience spanning multiple companies and industries. Pieter van der has held various titles such as Controller, Director of Finance, Financial Controller, and Financial Department Manager, showcasing their expertise in managing finances, reports, budgets, forecasts, and annual reporting. Throughout their career, Pieter has been responsible for financial departments, integration of systems, and being a key contact for various stakeholders such as accountants, lawyers, and insurance companies. Pieter van der holds a Bachelor's degree in Economics and Taxes from HAN University of Applied Sciences, as well as a Bachelor's degree in Financial Reporting and Analysis from NCOI Opleidingen.
This person is not in any teams
Julius Clinical
At Julius Clinical, science is the foundation. Combined with flexibility, creativity, and innovation, our scientific approach enables fast, efficient, and high quality execution of complex clinical development programs. Our skilled and loyal networks of investigators all around the world allow us to offer superior recruitment in therapeutic area’s such as cardiology, diabetes, CNS and infectious diseases. Our partners include leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators. We focus on clinical trials that are likely to have a major impact on medicine and on people’s lives. This type of demanding research requires more than a ‘one-size-fits-all’ approach, and our fusion of scientific and operational expertise enables to deliver results efficiently, on time and budget. Julius Clinical has on its staff internationally recognised academic leaders who are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility, combined with personal links with peers around the world, means that the company has a truly global reach and reputation. Through our global networks we can quickly select the most appropriate and high-performing sites to take part in a trial, and ensure that investigators are inspired and motivated.